Antibody data
- Antibody Data
- Antigen structure
- References [13]
- Comments [0]
- Validations
- Western blot [3]
- ELISA [1]
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- H00003845-M01 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#H00003845-M01, RRID:AB_540078
- Product name
- Mouse Monoclonal KRAS Antibody
- Antibody type
- Monoclonal
- Description
- IgG purified. KRAS - v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.1 mg
- Storage
- Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Submitted references Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.
K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function.
Single Cell Immuno-Laser Microdissection Coupled to Label-Free Proteomics to Reveal the Proteotypes of Human Brain Cells After Ischemia.
Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.
Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.
Evidence for aldosterone-dependent growth of renal cell carcinoma.
Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.
The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis.
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
Progesterone receptor activation of extranuclear signaling pathways in regulating p53 expression in vascular endothelial cells.
Analysis of k-ras nuclear expression in fibroblasts and mesangial cells.
Sherekar M, Han SW, Ghirlando R, Messing S, Drew M, Rabara D, Waybright T, Juneja P, O'Neill H, Stanley CB, Bhowmik D, Ramanathan A, Subramaniam S, Nissley DV, Gillette W, McCormick F, Esposito D
The Journal of biological chemistry 2020 Jan 24;295(4):1105-1119
The Journal of biological chemistry 2020 Jan 24;295(4):1105-1119
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.
Ahmed TA, Adamopoulos C, Karoulia Z, Wu X, Sachidanandam R, Aaronson SA, Poulikakos PI
Cell reports 2019 Jan 2;26(1):65-78.e5
Cell reports 2019 Jan 2;26(1):65-78.e5
K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function.
Cao S, Chung S, Kim S, Li Z, Manor D, Buck M
The Journal of biological chemistry 2019 Apr 26;294(17):7068-7084
The Journal of biological chemistry 2019 Apr 26;294(17):7068-7084
Single Cell Immuno-Laser Microdissection Coupled to Label-Free Proteomics to Reveal the Proteotypes of Human Brain Cells After Ischemia.
García-Berrocoso T, Llombart V, Colàs-Campàs L, Hainard A, Licker V, Penalba A, Ramiro L, Simats A, Bustamante A, Martínez-Saez E, Canals F, Sanchez JC, Montaner J
Molecular & cellular proteomics : MCP 2018 Jan;17(1):175-189
Molecular & cellular proteomics : MCP 2018 Jan;17(1):175-189
Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
Kuracha MR, Thomas P, Loggie BW, Govindarajan V
PloS one 2017;12(6):e0179510
PloS one 2017;12(6):e0179510
miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.
Forzati F, De Martino M, Esposito F, Sepe R, Pellecchia S, Malapelle U, Pellino G, Arra C, Fusco A
BMC cancer 2017 Mar 4;17(1):170
BMC cancer 2017 Mar 4;17(1):170
Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.
Madureira PA, Bharadwaj AG, Bydoun M, Garant K, O'Connell P, Lee P, Waisman DM
Oncotarget 2016 Jul 26;7(30):47720-47737
Oncotarget 2016 Jul 26;7(30):47720-47737
Evidence for aldosterone-dependent growth of renal cell carcinoma.
King S, Bray S, Galbraith S, Christie L, Fleming S
International journal of experimental pathology 2014 Aug;95(4):244-50
International journal of experimental pathology 2014 Aug;95(4):244-50
Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.
Ambrosini G, Khanin R, Carvajal RD, Schwartz GK
Molecular cancer therapeutics 2014 Aug;13(8):2073-80
Molecular cancer therapeutics 2014 Aug;13(8):2073-80
The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis.
Subramani A, Alsidawi S, Jagannathan S, Sumita K, Sasaki AT, Aronow B, Warnick RE, Lawler S, Driscoll JJ
Scientific reports 2013;3:2392
Scientific reports 2013;3:2392
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F
International journal of cancer 2013 Sep 1;133(5):1259-65
International journal of cancer 2013 Sep 1;133(5):1259-65
Progesterone receptor activation of extranuclear signaling pathways in regulating p53 expression in vascular endothelial cells.
Hsu SP, Lee WS
Molecular endocrinology (Baltimore, Md.) 2011 Mar;25(3):421-32
Molecular endocrinology (Baltimore, Md.) 2011 Mar;25(3):421-32
Analysis of k-ras nuclear expression in fibroblasts and mesangial cells.
Fuentes-Calvo I, Blázquez-Medela AM, Santos E, López-Novoa JM, Martínez-Salgado C
PloS one 2010 Jan 14;5(1):e8703
PloS one 2010 Jan 14;5(1):e8703
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - Western blot analysis of KRAS expression in lysates from human lung cancer cell lines: H23, H358, A549, and H441. Image from verified customer review.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - Analysis of KRAS expression in transfected 293T cell line by KRAS monoclonal antibody (M01), clone 3B10-2F2.Lane 1: KRAS transfected lysate(21 KDa).Lane 2: Non-transfected lysate.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - KRAS monoclonal antibody (M01), clone 3B10-2F2 Analysis of KRAS expression in HeLa.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- ELISA: KRAS Antibody (3B10-2F2) [H00003845-M01] - Detection limit for recombinant GST tagged KRAS is approximately 1ng/ml as a capture antibody.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunocytochemistry/Immunofluorescence: KRAS Antibody (3B10-2F2) [H00003845-M01] - Analysis of monoclonal antibody to KRAS on HeLa cell. Antibody concentration 10 ug/ml.